[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640517":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":145,"collaborators":24,"id":147,"slug":148,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":24,"eligibilityCriteria":153,"healthyVolunteers":149,"sex":154,"minAge":155,"maxAge":24,"enrollmentInfo":156,"targetDuration":24,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":24,"overallStatus":118,"whyStopped":24,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},{"fullName":5,"class":6},"NEOK Bio, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","NEOK002",[13],"Drug: NEOK002",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Recommended Dose of NEOK002 for Expansion",[18],"Drug: NEOK002 RDE",[20,25],{"type":21,"name":11,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Escalating doses of NEOK002",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"NEOK002 RDE","Recommended NEOK002 dose(s) for Expansion",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Beth Lepping, RN, BSN, MS","CONTACT","610-207-2119","blepping@neokbio.com",[36,52,67,82,95,107,117,131],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Memorial Sloan Kettering Cancer Center","NOT_YET_RECRUITING","New York","10065","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-74.00597,40.71427,{"lat":47,"lon":46},[50],{"name":24,"role":32,"phone":51,"phoneExt":24,"email":24},"646-888-4167",{"facility":53,"status":38,"city":54,"state":55,"zip":56,"country":41,"countryCode":42,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":44,"coordinates":58},[59,60],-86.78444,36.16589,{"lat":60,"lon":59},[63],{"name":64,"role":32,"phone":65,"phoneExt":24,"email":66},"Tracey Zimmer","972-566-3000","Tracey.Zimmer@scri.com",{"facility":68,"status":38,"city":69,"state":70,"zip":71,"country":41,"countryCode":42,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"NEXT Oncology","Austin","Texas","78758",{"type":44,"coordinates":73},[74,75],-97.74306,30.26715,{"lat":75,"lon":74},[78],{"name":79,"role":32,"phone":80,"phoneExt":24,"email":81},"Heather Watson","737-610-5202","hwatson@nextoncology.com",{"facility":68,"status":38,"city":83,"state":70,"zip":84,"country":41,"countryCode":42,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Dallas","78299",{"type":44,"coordinates":86},[87,88],-96.80667,32.78306,{"lat":88,"lon":87},[91],{"name":92,"role":32,"phone":93,"phoneExt":24,"email":94},"Mofopefoluwa \"Fope\" Akinwale","972-893-8800","fakinwale@nextoncology.com",{"facility":96,"status":38,"city":97,"state":70,"zip":98,"country":41,"countryCode":42,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"MD Anderson Cancer Center","Houston","77030",{"type":44,"coordinates":100},[101,102],-95.36327,29.76328,{"lat":102,"lon":101},[105],{"name":24,"role":32,"phone":106,"phoneExt":24,"email":24},"713-563-1055",{"facility":68,"status":38,"city":97,"state":70,"zip":108,"country":41,"countryCode":42,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"77054",{"type":44,"coordinates":110},[101,102],{"lat":102,"lon":101},[113],{"name":114,"role":32,"phone":115,"phoneExt":24,"email":116},"Emma Morales","832-384-7912","emorales@nextoncology.com",{"facility":68,"status":118,"city":119,"state":70,"zip":120,"country":41,"countryCode":42,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"RECRUITING","San Antonio","75039",{"type":44,"coordinates":122},[123,124],-98.49363,29.42412,{"lat":124,"lon":123},[127],{"name":128,"role":32,"phone":129,"phoneExt":24,"email":130},"Jordan Georg","210-580-9521","Jgeorg@nextoncology.com",{"facility":68,"status":38,"city":132,"state":133,"zip":134,"country":41,"countryCode":42,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Fairfax","Virginia","22031",{"type":44,"coordinates":136},[137,138],-77.30637,38.84622,{"lat":138,"lon":137},[141],{"name":142,"role":32,"phone":143,"phoneExt":24,"email":144},"Maybelle De La Rosa","703-783-4518","Mdelarosa@nextoncology.com",{"type":146,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100640517","phase-1-a-study-of-neok002-an-egfr-and-muc1-targeting-bispecific-adc-in-participants-with-select-solid-tumors-100640517",false,"NCT07612189","A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors","A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug, Conjugate in Participants With Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Participants must have locally advanced or metatstatic disease in a select tumor type, for which no standard therapy is available.\n* Participants must have at least 1 measurable target lesion based on RECIST v1.1.\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate hematologic, hepatic, and renal function.\n* Participants should have available archived tumor tissue from their most recent biopsy.\n\nKey Exclusion Criteria:\n\n* Participant's most recent systemic anti-cancer treatment was an ADC with a topoisomerase 1-inhibitor payload component.\n* Participant with known symptomatic central nervous system (CNS) metastases or any evidence of leptomeningeal disease or evidence of unstable CNS metastases, even if asymptomatic.\n* Participants with a known history of interstitial lung disease (ILD) requiring steroid treatment, or for whom suspected ILD cannot be ruled out by imaging at screening.\n* Participants with clinically severe pulmonary compromise due to intercurrent pulmonary illness and\u002For pulmonary disorder requiring supplemental oxygen or any prior pneumonectomy.\n* Participants with a QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec.","ALL","18 Years",{"count":157,"type":158},155,"ESTIMATED","INTERVENTIONAL",[161],"PHASE1","This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).",[164],"Locally Advanced (Unresectable) or Metastatic Solid Tumors","2026-05-28",{"date":167,"type":168},"2026-06-01","ACTUAL",{"date":170,"type":168},"2026-04-22",{"date":172,"type":158},"2029-02",{"name":5,"class":6},8]